Latest Sante Ventures Stories
Financing provides for the development of Lumos Pharma's lead compound, a novel treatment for Creatine Transporter Deficiency AUSTIN, Texas, Feb 4, 2014 /PRNewswire/ -- Lumos Pharma, an early stage biopharmaceutical development company, announced today that it has raised $14 million in Series A financing. The round was co-led by Sante Ventures and New Enterprise Associates (NEA). Lumos Pharma will use the financing to support the preclinical and clinical development of its lead...
- A stinking tobacco.
- Offal; waste animal product; organic matter unfit for consumption.